Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action.

摘要: Hyaluronan (HA) in combination with diclofenac is currently undergoing clinical trials as a topical preparation the management of osteoarthritic pain, basal-cell carcinoma and actinic keratosis. These are clearly diverse pathologies, but all cases substance P plays central role either directly or through secondary mediators such prostaglandin E2 nitric oxide. A common mechanism for HA these conditions may be ameliorating direct indirect effects P. Additionally, appears to depot hold epidermis, thereby prolonging its pharmacokinetic half-life. In rabbits, stenosis following balloon angioplasty prevented by subcutaneous dose HA, probably blockade cell-surface receptors (ICAM-1, CD44 & RHAMM). The physicochemical properties binding receptors, suggests that will have value novel drug delivery system.